Nanatinostat TFA
Based on 5 publication(s) in Google Scholar
Nanatinostat (CHR-3996) TFA is a potent, class I selective and orally active HDAC inhibitor with IC50s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat TFA has low activity against HDAC5 (IC50 of 200 nM) and HDAC6 (IC50 of 2100 nM). Nanatinostat TFA induces apoptosis in myeloma cells. Nanatinostat TFA has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 1256448-48-2
- Formula: C22H20F4N6O4
- Molecular Weight:508.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Nanatinostat TFA
More
Biological Activity
Description
IC50 & Target
[1]|
HDAC1 3 nM (IC50) |
HDAC2 4 nM (IC50) |
HDAC3 7 nM (IC50) |
HDAC 8 nM (IC50) |
HDAC5 200 nM (IC50) |
HDAC6 2100 nM (IC50) |
In Vitro
Nanatinostat (CHR-3996) (0.0001-1 μM; 48 hours) TFA inhibits the proliferation of myeloma cell lines, with LC50 values ranging from 30.3-97.6 nM in different cell lines[2].
Nanatinostat (250-100 nM; 8-48 hours)TFA induces apoptosis and increases the level of acetylated H3K9 in H929 and RPMI-8226 myeloma cell lines[2].
Nanatinostat (0-200 nM; 24 hours) TFA reduces the levels of IL-6 and VEGF secreted by bone marrow stromal cells in the co-culture system of bone marrow stromal cells and myeloma cells[2].
Nanatinostat (250 nM and 100 nM; 48 hours) TFA arrests the cell cycle at the G0/G1 phase in H929 and RPMI-8226 myeloma cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H929, RPMI-8226, KMS11, LP-1, MM1-S cells
-
Concentration:0.0001 μM, 0.001 μM, 0.01 μM, 0.1 μM, 1 μM
-
Incubation Time:48 hours
-
Result:The cell viability decreased.
-
Cell Line:H929 and RPMI-8226 myeloma cell lines
-
Concentration:100 nM (RPMI-8226 cells), 250 nM (H929 cells)
-
Incubation Time:8 hours, 24 hours, 48 hours
-
Result:The percentage of apoptotic cells increased, with an increase in both early and late apoptotic cells.
-
Cell Line:H929 and RPMI-8226 myeloma cell lines
-
Concentration:100 nM (RPMI-8226 cells), 250 nM (H929 cells)
-
Incubation Time:48 hours
-
Result:The cell cycle was arrested at the G0/G1 phase.
-
Cell Line:H929 and RPMI-8226 myeloma cell lines
-
Concentration:100 nM (RPMI-8226 cells), 250 nM (H929 cells)
-
Incubation Time:8 hours, 24 hours, 48 hours
-
Result:The pro-apoptotic DNase Endonuclease G and p53 downstream mediator Noxa were up-regulated, and caspase 9 was cleaved.
In Vivo
Nanatinostat (25-50 mg/kg; orally administered; once daily; for 19 days) TFA can significantly reduce tumor volume in a dose-dependent manner in the female BALB/c nude mouse LoVo human colon xenograft model[1].
Nanatinostat (30 mg/kg; orally administered; once daily; for 28 days) TFA can effectively inhibit tumor growth in the NOD/SCID IL2R gammanull mouse myeloma model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CrTac:NCr-Fox1(nu) mice (6-8 weeks old; inoculated bilaterally sc with 2 million human HCT116 colon carcinoma cells)[1].
-
Dosage:50 mg/kg
-
Administration:Orally administered, once daily, for 14 days
-
Result:Almost completely suppressed tumor growth, and the tumor concentration was high, with a tumor-to-plasma concentration ratio reflecting good distribution to the tumor.
-
Animal Model:Female BALB/c nude mice (inoculated with LoVo human colorectal xenograft)[1].
-
Dosage:25 mg/kg and 50 mg/kg
-
Administration:Orally administered, once daily, for 19 days
-
Result:Significantly reduced tumor volume, and the effect was dose-dependent.
-
Animal Model:NOD/SCID IL2R gammanull mice (inoculated subcutaneously with 2×106 H929 myeloma cells)[2].
-
Dosage:30 mg/kg
-
Administration:Orally administered, once daily, for up to 28 days
-
Result:Effectively inhibited tumor growth.
Chemical Information
-
CAS No. 1256448-48-2
-
Molecular Weight 508.43
-
Formula C22H20F4N6O4
-
SMILES
OC(C(F)(F)F)=O.FC(C=C1)=CC(C=C2)=C1N=C2CN[C@H]3[C@@]4([H])[C@]3([H])CN(C5=NC=C(C(NO)=O)C=N5)C4
-
Synonyms
CHR-3996 TFA
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. [Abstract]2022 Dec 16;82(24):4542-4554. PMID: 36102738 -
-
Cell Rep
Comprehensive mass spectrometry screening-derived atlas of HDAC inhibitors reveals histone-specific acetylation changes. [Abstract]2026 May 26;45(5):117289. PMID: 42030158 -
-
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
[1]. Moffat D, et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem. 2010 Dec 23;53(24):8663-78. [Content Brief]
[2]. Smith EM, et al. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget. 2015 Jul 10;6(19):17314-27. [Content Brief]
[3]. Banerji U, et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)